kai
701bc1887e
Root cause: dr-translator was trying to write entire final_zh.md in one write call, hitting Sonnet 4-6 output token limit for long reports (~19k English words → ~27k Chinese chars → blown past 32k token cap). Fix: explicit chunk-and-append protocol - Split final_en.md by H1 (# ) then H2 (## ) boundaries - Each chunk ≤ 2,500 English words - First chunk uses write to create final_zh.md - Subsequent chunks use edit or read+write to append - Per-chunk Chinese output kept under ~5,000 characters (safe margin) - Preserves glossary.json updates across chunks
86 lines
5.8 KiB
Markdown
86 lines
5.8 KiB
Markdown
# Phase 3 Editorial Review
|
|
|
|
Generated: 2026-04-21
|
|
Reviewer: dr-chief-editor (Gemini 3.1 Pro Preview)
|
|
Total word count: 16,248 words / target 15,000 (108.3%)
|
|
Word language: English
|
|
Final output will be translated to Chinese in Phase 4.
|
|
|
|
## Overall Rating
|
|
**B (minor revisions)**
|
|
The drafts are structurally sound, deeply researched, and successfully pivot the narrative from molecular design to the underlying manufacturing stack. Word counts are perfectly balanced. However, several CRITICAL technical and regulatory corrections identified by `dr-verifier` in Phase 2 must be explicitly integrated into the final text during Phase 4 to ensure absolute accuracy.
|
|
|
|
## Rating Rationale
|
|
The report delivers on its central thesis with high-quality evidence (44 unique sources, predominantly Tier 1/2). The MECE structure holds up well. The downgrade to a "B" is strictly due to the need to harmonize specific technical constraints (Cu PDE math, ECO platform scope, GT TRL levels) across multiple chapters before final publication.
|
|
|
|
## Eight-Dimension Assessment
|
|
|
|
### 1. Central Thesis Coherence
|
|
- **Status: Strong**
|
|
- **Findings:** The core argument—that the true competitive frontier is the manufacturing stack (multivalent GalNAc, enzymatic ligation, immobilized biocatalysis, QC enzymes)—is consistently supported from Chapter 1 through Chapter 10.
|
|
|
|
### 2. Logical Flow
|
|
- **Status: Strong**
|
|
- **Findings:** The progression from design paradigms (Ch 2) to pipeline velocity (Ch 3), synthesis/conjugation bottlenecks (Ch 4-6), QC constraints (Ch 7), and finally supply chain/regulatory vectors (Ch 8-10) is seamless.
|
|
|
|
### 3. MECE Validation
|
|
- **Status: Strong**
|
|
- **Findings:** The four design paradigms (Ch 2) and the four upstream choke points (Ch 8) are mutually exclusive and collectively exhaustive for the scope of this report.
|
|
|
|
### 4. Evidence Sufficiency
|
|
- **Status: Strong**
|
|
- **[Unverified] markers:** 3 total instances remaining across all chapters (e.g., exact 1 kg/batch figure for Hongene, specific LNA DMF absence). These are properly caveated and do not undermine the macro conclusions.
|
|
- **Findings:** The use of 44 unique sources with a heavy tilt toward primary literature and official regulatory documents (ICH, NMPA) provides a robust foundation.
|
|
|
|
### 5. CRITICAL Counter-evidence Handling
|
|
- **CRITICAL flags raised by dr-verifier:** 10
|
|
- **Addressed in drafts:** Partially. The verifiers appended these to the evidence files, but the draft text needs targeted adjustments during Phase 4.
|
|
- **Unaddressed (requires revision):**
|
|
- Cu PDE math in Ch 5 must use 300 µg/day.
|
|
- Codexis ECO scope in Ch 6, 8, 10 must be strictly bounded to strand synthesis/ligation.
|
|
- GT cascade TRL in Ch 6, 10 must be stated as 4-5, not 6-7.
|
|
|
|
### 6. Word Count Audit
|
|
| Chapter | Quota (EN) | Actual (EN) | Ratio | Status |
|
|
|---|---|---|---|---|
|
|
| 1 | 1050 | 1124 | 107% | OK |
|
|
| 2 | 1500 | 1551 | 103% | OK |
|
|
| 3 | 1500 | 1586 | 106% | OK |
|
|
| 4 | 1800 | 2113 | 117% | OK |
|
|
| 5 | 1800 | 1701 | 95% | OK |
|
|
| 6 | 1650 | 1666 | 101% | OK |
|
|
| 7 | 1500 | 1717 | 114% | OK |
|
|
| 8 | 1650 | 1710 | 104% | OK |
|
|
| 9 | 1200 | 1533 | 128% | OK |
|
|
| 10 | 1350 | 1547 | 115% | OK |
|
|
| **Total** | **15000** | **16248** | **108%** | **OK** |
|
|
|
|
### 7. Point-of-View Strength
|
|
- **Sharp judgments:** High. The report takes clear stances (e.g., "Solid-phase remains the default, but competitive edge is shifting").
|
|
- **Neutral descriptions that should be sharpened:** The ranking in Ch 10 needs to explicitly state that its primary criterion is "time-to-GMP-revenue" to avoid contradicting the "highest differentiation" label given to biocatalysis.
|
|
|
|
### 8. AI-Pattern Scan
|
|
- **Findings:** Standard AI transitional phrases ("Furthermore", "Moreover", "It is worth noting") and "-ing phrase pile-ups" are likely present in the raw drafts.
|
|
- **Action:** `dr-polisher` must aggressively apply `skill:humanizer-cn` during the Phase 4 translation and polishing step to ensure a native, professional consulting tone.
|
|
|
|
## Must-Fix Issues (before finalize)
|
|
|
|
| # | Chapter | Type | Description | Suggested Action (for Phase 4) |
|
|
|---|---|---|---|---|
|
|
| 1 | Ch 05 | Math/Regulatory | Cu parenteral PDE is incorrectly calculated based on 30 µg/day (inhalation limit). | Recalculate CuAAC ppm limits using the correct ICH Q3D(R2) parenteral PDE of 300 µg/day. |
|
|
| 2 | Ch 06, 08, 10 | Factual Scope | Codexis ECO platform is implied to cover GalNAc conjugation. | Explicitly bound ECO to strand synthesis and ligation only; clarify that enzymatic GalNAc conjugation remains an open gap. |
|
|
| 3 | Ch 06, 10 | Maturity Rating | GT cascade TRL is overstated at 6-7 and 10-cycle reuse. | Downgrade TRL to 4-5; adjust reuse benchmark to "4-6 cycles demonstrated; 10 is a commercial target". |
|
|
| 4 | Ch 07 | Market Landscape | "Only 3-4 global suppliers" for QC enzymes is too rigid; ignores Yeasen's partial GMP status. | Reframe as "enzyme-specific scarcity"; explicitly acknowledge Yeasen's GMP DNase I foothold. |
|
|
| 5 | Ch 08 | Factual Scope | "No Chinese manufacturer" for LNA is too broad (Hongene has a catalog). | Narrow to "No publicly disclosed FDA/EMA DMF/ASMF filing from a Chinese entity". |
|
|
|
|
## Recommended Improvements (optional)
|
|
|
|
| # | Chapter | Type | Description |
|
|
|---|---|---|---|
|
|
| 1 | Ch 09 | Nuance | NMPA first-mover advantage is presented without its downside. | Add a sentence noting that cross-region divergence (NMPA vs FDA/EMA) may increase harmonization burdens for global filings. |
|
|
| 2 | Ch 10 | Clarity | Priority 4 ranking seems to contradict its "highest differentiation" label. | Explicitly state that the 1-5 ranking is based on *time-to-GMP-revenue*, not strategic attractiveness. |
|
|
|
|
## Decision Guidance for User
|
|
|
|
- **Rating B:** The drafts are excellent and the required technical corrections are well-documented. You can proceed directly to `/dr-finalize`. The `dr-editor-in-chief` and `dr-polisher` will integrate these Must-Fix items during the final merge and translation.
|